Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects

0:00-12:37

He discusses the regulatory status of Lyme disease, which hit on secondary enpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.

B-

BiotechTV - News

@biotechtvnews

#valnevaceothomas #companyslymedisease #pipelineprojects #lifesciences

The Nile